Presidio Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   13 Diseases  2 Products   1 Trial   100 News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
STORM-C-1, NCT02961426: Strategic Transformation of the Market of HCV Treatments

Active, not recruiting
2/3
603
RoW
sofosbuvir + ravidasvir, ravisdasvir: PPI-668
Drugs for Neglected Diseases, Ministry of Health, Malaysia, Ministry of Health, Thailand, National Science and Technology Development Agency, Thailand
Hepatitis C
08/21
03/24
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Completed
2/3
322
RoW
Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668
Muhammad Radzi Abu Hassan
Hepatitis C
12/23
03/24
ChiCTR2000041303: Study on the effect of food on ASC16 tablets pharmacokinetics

Completed
1
16
 
ASC16 tablet
Hu'nan Provincial Maternal and Child Health Care Hospital; Ascletis BioScience Co., Ltd., Self-finance
Basic Science
 
 
ChiCTR2000040851: The pharmacokinetics of single and multiple doses of ASC16 quadruplex administration

Completed
1
64
 
ASC16 (200 mg, 1 tablet) ;ASC08 (100 mg, 1tablet) ;RTV (100 mg, 1tablet) ;RBV (500 mg, 5tablet) ;ASC16 (200 mg, 1 tablet) +ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet) + RBV (500 mg, 5 tablets) ;Group F: ASC16 (200 mg, 1 tablet, QD) + ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet, BID) + RBV (500 mg, 5 tablets, BID)
Nanning Second People's Hospital; Ascletis BioScience Co., Ltd., self-finance
Basic Science
 
 
NS5B NNuC-PPI-383 / Presidio Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Asclevir (ravidasvir) / Presidio Pharma, Ascletis, Pharco Pharmaceuticals
STORM-C-1, NCT02961426: Strategic Transformation of the Market of HCV Treatments

Active, not recruiting
2/3
603
RoW
sofosbuvir + ravidasvir, ravisdasvir: PPI-668
Drugs for Neglected Diseases, Ministry of Health, Malaysia, Ministry of Health, Thailand, National Science and Technology Development Agency, Thailand
Hepatitis C
08/21
03/24
NCT04885855: 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Completed
2/3
322
RoW
Sofosbuvir 400 MG, Grateziano, Ravidasvir 200mg, PPI-668
Muhammad Radzi Abu Hassan
Hepatitis C
12/23
03/24
ChiCTR2000041303: Study on the effect of food on ASC16 tablets pharmacokinetics

Completed
1
16
 
ASC16 tablet
Hu'nan Provincial Maternal and Child Health Care Hospital; Ascletis BioScience Co., Ltd., Self-finance
Basic Science
 
 
ChiCTR2000040851: The pharmacokinetics of single and multiple doses of ASC16 quadruplex administration

Completed
1
64
 
ASC16 (200 mg, 1 tablet) ;ASC08 (100 mg, 1tablet) ;RTV (100 mg, 1tablet) ;RBV (500 mg, 5tablet) ;ASC16 (200 mg, 1 tablet) +ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet) + RBV (500 mg, 5 tablets) ;Group F: ASC16 (200 mg, 1 tablet, QD) + ASC08/ R (100 mg/100 mg, 1 tablet /1 tablet, BID) + RBV (500 mg, 5 tablets, BID)
Nanning Second People's Hospital; Ascletis BioScience Co., Ltd., self-finance
Basic Science
 
 
NS5B NNuC-PPI-383 / Presidio Pharma
No trials found

Download Options